Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters

Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259

Model-based Analysis of ChIP-Seq (MACS)

Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386

Differential expression analysis for sequence count data

Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581

Integrative genomics viewer

Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390

Integrating single-cell transcriptomic data across different conditions, technologies, and species

Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174

Scenic: single-cell regulatory network inference and clustering.

Aibar, S., González-Blas, C. B., Moerman, T., Huynh-Thu, V. A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.-C., Geurts, P., Aerts, J., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4463 · Cited by 6,520

Improved vectors and genome-wide libraries for CRISPR screening

Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239

Genome-scale CRISPR-Cas9 knockout screening in human cells

Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234

Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9

Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637

Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies

Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256

IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models

Jaspers, J. E., Khan, J. F., Godfrey, W. D., Lopez, A. V., Ciampricotti, M., Rudin, C. M., & Brentjens, R. J. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166028 · Cited by 191

H3K27me3 conditions chemotolerance in triple-negative breast cancer

Marsolier, J., Prompsy, P., Durand, A., Lyne, A.-M., Landragin, C., Trouchet, A., Bento, S. T., Eisele, A. S., Foulon, S., Baudre, L., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01047-6 · Cited by 194

STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models

Berger, G., Knelson, E. H., Jimenez-Macias, J. L., Nowicki, M. O., Han, S., Panagioti, E., Lizotte, P. H., Adu-Berchie, K., Stafford, A., Dimitrakakis, N., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111003119 · Cited by 179

Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect

Nishiga, Y., Drainas, A. P., Baron, M., Bhattacharya, D., Barkal, A. A., Ahrari, Y., Mancusi, R. A., Ross, J., Takahashi, N., Thomas, A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00456-0 · Cited by 180

Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma

Wu, M., Shi, L., Dubrot, J., Merritt, J., Vijay, V., Wei, T.-Y., Kessler, E., Olander, K. E., Adil, R., Pankaj, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1077 · Cited by 158

The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity

Davies, A., Zoubeidi, A., Beltran, H., & Selth, L. A. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0225 · Cited by 170

Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC

Nguyen, E. M., Taniguchi, H., Chan, J. M., Zhan, Y. A., Chen, X., Qiu, J. J., de Stanchina, E., Allaj, V., Shah, N., Uddin, F. Z., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.05.014 · Cited by 144

Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer

Sen, T., Takahashi, N., Chakraborty, S., Takebe, N., Nassar, A. H., Karim, N. A., Puri, S., & Naqash, A. R. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00914-x · Cited by 143

Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing

Hiatt, J. B., Sandborg, H., Garrison, S. M., Arnold, H. U., Liao, S.-Y., Norton, J. P., Friesen, T. J., Wu, F., Sutherland, K. D., Rienhoff, H. Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1128 · Cited by 138

TET2-mediated tumor cGAS triggers endothelial STING activation to regulate vasculature remodeling and anti-tumor immunity in liver cancer

Lv, H., Zong, Q., Chen, C., Lv, G., Xiang, W., Xing, F., Jiang, G., Yan, B., Sun, X., Ma, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-43743-9 · Cited by 117

TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity

Tani, T., Mathsyaraja, H., Campisi, M., Li, Z., Haratani, K., Fahey, C. G., Ota, K., Mahadevan, N. R., Shi, Y., Saito, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0700 · Cited by 116

MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer

Kitajima, S., Tani, T., Springer, B. F., Campisi, M., Osaki, T., Haratani, K., Chen, M., Knelson, E. H., Mahadevan, N. R., Ritter, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.015 · Cited by 107

Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer

Sholl, L. M. (2021) · Modern Pathology · doi:10.1038/s41379-021-00932-5 · Cited by 108

Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation

Rudin, C. M., Balli, D., Lai, W.-C. V., Richards, A. L., Nguyen, E. M., Egger, J. V., Choudhury, N. J., Sen, T., Chow, A. T., Poirier, J. T., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.05.008 · Cited by 106

Targeting DHX9 Triggers Tumor-Intrinsic Interferon Response and Replication Stress in Small Cell Lung Cancer

Murayama, T., Nakayama, J., Jiang, X., Miyata, K., Morris, A. D., Cai, K. Q., Prasad, R. M., Ma, X., Efimov, A., Belani, N., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0486 · Cited by 112

Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes

Sengupta, S., Das, S., Crespo, Â. C., Cornel, A. M., Patel, A. G., Mahadevan, N. R., Campisi, M., Ali, A. K., Sharma, B., Rowe, J. H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00427-5 · Cited by 101

MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis

Κhan, P., Siddiqui, J. A., Kshirsagar, P., Venkata, R. C., Maurya, S. K., Mirzapoiazova, T., Perumal, N., Chaudhary, S., Kanchan, R. K., Fatima, M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01695-6 · Cited by 96

Epigenetic state determines the in vivo efficacy of STING agonist therapy

Falahat, R., Berglund, A., Perez-Villarroel, P., Putney, R. M., Hamaidi, I., Kim, S., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2023) · Nature Communications · doi:10.1038/s41467-023-37217-1 · Cited by 94

Activation of Tumor-Cell STING Primes NK-Cell Therapy

Knelson, E. H., Ivanova, E. V., Tarannum, M., Campisi, M., Lizotte, P. H., Booker, M. A., Ozgenc, I., Noureddine, M., Meisenheimer, B., Chen, M., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0017 · Cited by 88

The role of stem cells in small-cell lung cancer: Evidence from chemoresistance to immunotherapy

Guo, W., Qiao, T., & Li, T. X. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.11.006 · Cited by 86

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes

Venkadakrishnan, V. B., Presser, A. G., Singh, R., Booker, M. A., Traphagen, N. A., Weng, K., Voss, N. C. E., Mahadevan, N. R., Mizuno, K., Puca, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51156-5 · Cited by 84

Killing SCLC: insights into how to target a shapeshifting tumorPreprint

Sutherland, K. D., Ireland, A. S., & Oliver, T. G. (2022) · Genes & Development · doi:10.1101/gad.349359.122 · Cited by 78

KDM6A epigenetically regulates subtype plasticity in small cell lung cancer

Duplaquet, L., Li, Y., Booker, M. A., Xie, Y., Olsen, S. N., Patel, R. A., Hong, D., Hatton, C., Denize, T., Walton, E., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01210-z · Cited by 77

Understanding and therapeutically exploiting cGAS/STING signaling in glioblastoma

Low, J., Brown, M. C., Reitman, Z. J., Bernstock, J. D., Markert, J. M., Friedman, G. K., Waitkus, M. S., Bowie, M. L., & Ashley, D. M. (2024) · Journal of Clinical Investigation · doi:10.1172/jci163452 · Cited by 81

Challenges of small cell lung cancer heterogeneity and phenotypic plasticity

Simpson, K., Rothwell, D. G., Blackhall, F. H., & Dive, C. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00803-0 · Cited by 70

AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution

Schade, A. E., Perurena, N., Yang, Y., Rodriguez, C. L., Krishnan, A., Gardner, A., Loi, P., Xu, Y., Nguyen, V. T. M., Mastellone, G. M., et al. (2024) · Nature · doi:10.1038/s41586-024-08031-6 · Cited by 72

ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer

Taniguchi, H., Chakraborty, S., Takahashi, N., Banerjee, A., Caeser, R., Zhan, Y. A., Tischfield, S. E., Chow, A. T., Nguyen, E. M., Quintanal-Villalonga, À., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado4618 · Cited by 75

Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer

Duplaquet, L., So, K., Ying, A. W., Choudhuri, S. P., Li, X., Xu, G. D., Li, Y., Qiu, X., Li, R., Singh, S., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.06.012 · Cited by 66

Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy

Chen, Y., Li, H., & Fan, Y. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102606 · Cited by 65

Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study

Xie, M., Vuko, M., Rodriguez‐Canales, J., Zimmermann, J., Schick, M., O’Brien, C., Paz-Ares, L. G., Goldman, J. W., Garassino, M. C., Gay, C. M., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02014-x · Cited by 59

Genetically-engineered mouse models of small cell lung cancer: the next generation

Oser, M. G., MacPherson, D. P., Oliver, T. G., Sage, J., & Park, K.-S. (2024) · Oncogene · doi:10.1038/s41388-023-02929-7 · Cited by 54

Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification

Caliman, E., Fancelli, S., Petroni, G., Michelet, M. R. G., Cosso, F., Ottanelli, C., Mazzoni, F., Voltolini, L., Pillozzi, S., & Antonuzzo, L. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.11.014 · Cited by 54

Lineage Plasticity: The New Cancer Hallmark on the Block

Mehta, A., & Stanger, B. Z. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1067 · Cited by 54

Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity

Redín, E., Quintanal-Villalonga, À., & Rudin, C. M. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.07.008 · Cited by 51

Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer

Hong, D., Knelson, E. H., Li, Y., Durmaz, Y. T., Gao, W., Walton, E., Vajdi, A., Thai, T. C., Sticco-Ivins, M. A., Sabet, A. H., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1991 · Cited by 48

Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1

Chen, H.-Y., Durmaz, Y. T., Li, Y., Sabet, A. H., Vajdi, A., Denize, T., Walton, E., Laimon, Y. N., Doench, J. G., Mahadevan, N. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31998-7 · Cited by 47

ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer

Mota, I. A., Patrucco, E., Mastini, C., Mahadevan, N. R., Thai, T. C., Bergaggio, E., Cheong, T.-C., Leonardi, G. C., Atabay, E. K., Campisi, M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00591-2 · Cited by 47

Microenvironment shapes small-cell lung cancer neuroendocrine states and presents therapeutic opportunities

Desai, P. A., Takahashi, N., Kumar, R., Nichols, S., Malin, J., Hunt, A. L., Schultz, C. W., Cao, Y., Tillo, D., Nousome, D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101610 · Cited by 44

Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling

Zarif, T. E., Meador, C. B., Qiu, X., Seo, J.-H., Davidsohn, M. P., Savignano, H., Lakshminarayanan, G., McClure, H. M., Canniff, J., Fortunato, B. J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0466 · Cited by 42

Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy

Shen, L., Wang, B., Wang, S., Ji, S., Fu, M., Wang, S.-W., Hou, W., Dai, X., & Liu, H. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02133 · Cited by 39

Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and -Low Small Cell Lung Cancer

Dóra, D., Rivard, C. J., Yu, H., Pickard, S. L., László, V., Harkó, T., Megyesfalvi, Z., Dinya, E., Gerdán, C., Szegvári, G., et al. (2021) · Biology · doi:10.3390/biology10060502 · Cited by 37

Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions

Hiatt, J. B., Doebley, A.-L., Arnold, H. U., Adil, M., Sandborg, H., Persse, T. W., Ko, M., Wu, F., Quintanal-Villalonga, À., Santana-Dávila, R., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk2082 · Cited by 40

Advancing therapeutics in small-cell lung cancer

Thomas, A., Mohindroo, C., & Giaccone, G. (2025) · Nature Cancer · doi:10.1038/s43018-025-00996-1 · Cited by 38

MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer

Alburquerque-Béjar, J. J., Navajas-Chocarro, P., Saigí, M., Ferrero-Andres, A., Morillas, J. M., Vilarrubi, A., Gómez, A., Mate, J. L., Muñoz-Mármol, A. M., Romero, O. A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101006 · Cited by 42

SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing

Redín, E., Sridhar, H., Zhan, Y. A., Mello, B. P., Zhong, H., Durani, V., Sabet, A., Manoj, P., Linkov, I., Qiu, J. J., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01572-3 · Cited by 37

Tackling the current dilemma of immunotherapy in extensive-stage small cell lung cancer: A promising strategy of combining with radiotherapy

Kang, K., Wu, Y., Yao, Z., & Lü, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216239 · Cited by 39

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives

Zhang, S., & Cheng, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1142081 · Cited by 35

Predictive biomarkers for immunotherapy response in extensive-stage SCLC

Zhu, L., & Qin, J. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05544-x · Cited by 38

Targeting the epigenetic processes to enhance antitumor immunity in small cell lung cancer

Luo, H., Shan, J., Zhang, H., Song, G., Li, Q., & Xu, C. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.018 · Cited by 34

Emerging role of chemokines in small cell lung cancer: Road signs for metastasis, heterogeneity, and immune response

Κhan, P., Fatima, M., Khan, M. A., Batra, S. K., & Nasser, M. W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.11.005 · Cited by 34

Targeting the loss of cGAS / STING signaling in cancer

Sasaki, N., Homme, M., & Kitajima, S. (2023) · Cancer Science · doi:10.1111/cas.15913 · Cited by 34

A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Choudhury, N. J., Lai, W.-C. V., Makhnin, A., Heller, G., Eng, J., Li, B. T., Preeshagul, I. R., Santini, F. C., Offin, M. D., Ng, K., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3383 · Cited by 33

Targeting STING to generate therapeutic anti-tumor immunity

Fahey, C. G., Cordova, A. F., Gedeon, P. C., & Barbie, D. A. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.12.002 · Cited by 36

Extensive‐stage small‐cell lung cancer: Current management and future directions

Yu, Y., Chen, K., & Fan, Y. (2022) · International Journal of Cancer · doi:10.1002/ijc.34346 · Cited by 33

Recent advances and future strategies in first-line treatment of ES-SCLC

Gómez‐Randulfe, I., Leporati, R., Gupta, B., Liu, S. V., & Califano, R. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113581 · Cited by 32

Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer

Jin, Y., Wu, Y., Reuben, A., Zhu, L., Gay, C. M., Wu, Q., Zhou, X., Mo, H., Zheng, Q., Ren, J., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00703-x · Cited by 34

Immunotherapy in Extensive-Stage Small Cell Lung Cancer

Sayed, R. E., & Blais, N. (2021) · Current Oncology · doi:10.3390/curroncol28050347 · Cited by 31

Facts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer

Zugazagoitia, J., Charris, H. R. O., Baena, J., Ucero, A. C., & Paz-Ares, L. G. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1159 · Cited by 34

New developments in immunotherapy for SCLC

Dolkar, T., Gates, C., Hao, Z., & Munker, R. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009667 · Cited by 31

Lineage plasticity and histological transformation: tumor histology as a spectrum

Li, X., Gardner, E. E., Molina‐Pinelo, S., Wilhelm, C., Mu, P., & Quintanal-Villalonga, À. (2025) · Cell Research · doi:10.1038/s41422-025-01180-x · Cited by 33

Polycomb Directed Cell Fate Decisions in Development and Cancer

German, B., & Ellis, L. (2022) · Epigenomes · doi:10.3390/epigenomes6030028 · Cited by 34

A multiplexed in vivo approach to identify driver genes in small cell lung cancer

Lee, M. C., Cai, H., Murray, C. W., Li, C., Shue, Y. T., Andrejka, L., He, A., Holzem, A. M. E., Drainas, A. P., Ko, J. H., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.111990 · Cited by 30

Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1

Li, Y., Mahadevan, N. R., Duplaquet, L., Hong, D., Durmaz, Y. T., Jones, K. L., Cho, H., Morrow, M., Protti, A., Poitras, M. J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101282 · Cited by 30

Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review

Xiong, J., Barayan, R., Louie, A. V., & Lok, B. H. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.008 · Cited by 31

Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

Murayama, T., Mahadevan, N. R., Meador, C. B., Ivanova, E. V., Pan, Y., Knelson, E. H., Tani, T., Nakayama, J., Ma, X., Thai, T. C., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0360 · Cited by 29

Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer

Chen, T., Wang, M., Chen, Y., Cao, Y., & Liu, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01283-9 · Cited by 28

Chemical biology and pharmacology of histone lysine methylation inhibitors

Barghout, S. H., Machado, R. A. C., & Baršytė-Lovejoy, D. (2022) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2022.194840 · Cited by 29

An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC

Fousek, K., Horn, L. A., Qin, H., Dahut, M., Iida, M., Yacubovich, D., Hamilton, D. H., Thomas, A., Schlom, J., & Palena, C. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.11.008 · Cited by 27

Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance

Hwang, S., Hong, T. H., Kim, H. K., Choi, Y. S., Zo, J. I., Shim, Y. M., Han, J., Ahn, Y. C., Pyo, H., Noh, J. M., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100184 · Cited by 27

Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer

Otegui, N., Houry, M., Arozarena, I., Serrano, D., Redín, E., Expósito, F., León, S., Valencia, K., Montuenga, L. M., & Calvo, A. (2023) · Cancers · doi:10.3390/cancers15123076 · Cited by 27

A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer

Eglenen-Polat, B., Kowash, R. R., Huang, H.-C., Siteni, S., Zhu, M., Chen, K., Bender, M. E., Mender, I., Stastny, V., Drapkin, B. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44861-8 · Cited by 26

A STAT3–STING–IFN axis controls the metastatic spread of small cell lung cancer

Guanizo, A. C., Luong, Q., Jayasekara, W. S. N., de Geus, E. D., Inampudi, C., Xue, V. S., Chen, J., de Weerd, N. A., Matthews, A. Y., Gantier, M. P., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-02014-5 · Cited by 28

Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers

Venkadakrishnan, V. B., Yamada, Y., Weng, K., Idahor, O., & Beltran, H. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0045 · Cited by 28

Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer

Dóra, D., Rivard, C. J., Yu, H., Pickard, S. L., László, V., Harkó, T., Megyesfalvi, Z., Gerdán, C., Dinya, E., Höetzenecker, K., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03270-w · Cited by 24

Harnessing αβ T cell receptor mechanobiology to achieve the promise of immuno-oncology

Reinherz, E. L., Hwang, W., & Lang, M. J. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2215694120 · Cited by 22

IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1/-L1 therapy in SCLC

Cui, Y., Qiu, T., Wang, J., Liu, X., Luo, L., Yin, J.-Z., Zhi, X., Wang, W., Feng, G., Wu, C., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02383-x · Cited by 22

Immunogenicity of small‐cell lung cancer associates with STING pathway activation and is enhanced by ATR and TOP1 inhibition

Li, X., Li, Y., Zhao, Z., Miao, N., Liu, G., Deng, L., Wei, S., & Hou, J. (2022) · Cancer Medicine · doi:10.1002/cam4.5109 · Cited by 24

Advances in Lung Cancer Basic and Translational Research in 2025 – Overview and Perspectives Focusing on NSCLC

Mascaux, C., Sen, T., Sánchez‐Céspedes, M., Ortiz‐Cuaran, S., Bossé, Y., Dammeijer, F. F., Cavic, M. R., Barr, M. P., Arulananda, S., Armisén, R., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.05.024 · Cited by 22

Immune checkpoint blockade for cancer therapy: current progress and perspectives

Ye, H., Liao, W., Pan, J., Shi, Y. P., & Wang, Q. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2300492 · Cited by 23

Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer

Shirasawa, M., Yoshida, T., Shiraishi, K., Goto, N., Yagishita, S., Imabayashi, T., Matsumoto, Y., Masuda, K., Shinno, Y., Okuma, Y., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02427-3 · Cited by 18

In situ administration of STING-activating hyaluronic acid conjugate primes anti-glioblastoma immune response

Chellen, T., Bausart, M., Maus, P., Vanvarenberg, K., Limaye, N., Véronique Préat, A., & Malfanti, A. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101057 · Cited by 19

GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancer

Drainas, A. P., Hsu, W.-H., Dallas, A. E., Poltorack, C. D., Kim, J. W., He, A., Coles, G. L., Baron, M., Bassik, M. C., & Sage, J. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114606 · Cited by 21

Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients

Lorenzi, M., Resi, M. V., Bonanno, L., Frega, S., Maso, A. D., Ferro, A., Guarneri, V., & Pasello, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1308109 · Cited by 17

Small Cell Lung Cancer Neuronal Features and Their Implications for Tumor Progression, Metastasis, and Therapy

Hartmann, G. G., & Sage, J. (2024) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0265 · Cited by 17

Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer

Campisi, M., Osaki, T., Dryg, I., Stornante, C., Wolff, J., Weirather, J. L., Weaver, N. C., Tarannum, M., Gillanders, I., Bers, A. E., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.02.008 · Cited by 16

Effect of chromatin modifiers on the plasticity and immunogenicity of small-cell lung cancer

Kirk, N. A., Kim, K., & Park, K.-S. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00905-x · Cited by 17

Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

Peressini, M., García-Campelo, R., Massutí, B., Martí, C., Cobo, M., Gutiérrez, V., Dómine, M., Fuentes, J., Majem, M., de Castro, J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0104 · Cited by 16

Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer?

Tendler, S., & Rudin, C. M. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00148 · Cited by 16

Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming

Wang, H., Gao, N., Wang, L., Yang, F., Liu, B., Hu, X., Zhao, Y., Sha, R., Li, X., & Li, H. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103044 · Cited by 15

An in-silico analysis reveals further evidence of an aggressive subset of lung carcinoids sharing molecular features of high-grade neuroendocrine neoplasms

Pelosi, G., Melocchi, V., Dama, E., Hofman, P. M., Luca, M. D., Albini, A., Gemelli, M., Ricotta, R., Papotti, M. G., Rosa, S. L., et al. (2024) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2024.104882 · Cited by 15

Heterogeneity of molecular subtyping and therapy-related marker expression in primary tumors and paired lymph node metastases of small cell lung cancer

Zhu, Y., Ren, W., Li, S., Wu, J., Hu, X., Wang, H., Chi, K., Zhuo, M., & Lin, D. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03754-3 · Cited by 15

Immunotherapy for small cell lung cancer: current challenges and prospects

Zhong, J., Jie, G., Qin, H., Li, H., Chen, N. W., Aerxiding, P., Zou, X., & Niu, X. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00720-w · Cited by 14

Spliceosome inhibition induces Z-RNA and ZBP1-driven cell death in small cell lung cancer

Jiang, X., Ma, X., Zhou, Y., Liu, X., Zhang, T., Kim, W., Balachandran, S., & Cañadas, I. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116384 · Cited by 13

Lactate represses MHC-I antigen presentation via H4K5 lactylation-PRC2 in small cell lung cancer subtype A

Cai, Y., Li, X., Zhu, S., Wu, H., Nie, J., & Huang, F. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.116125 · Cited by 15

Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review

Meador, C. B., & Piotrowska, Z. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-867 · Cited by 14

Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targets

Jiang, J., Han, D., Wang, J., Wen, W., Zhang, R., & Qin, W. (2024) · MedComm · doi:10.1002/mco2.761 · Cited by 14

PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers

Gu, Y., Ly, A., Rodriguez, S., Zhang, H., Kim, J., Mao, Z., Sachdeva, A., Zomorodian, N., Pellegrini, M. A., Li, G., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101824 · Cited by 15

Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer

Chakraborty, S., Sen, U., Ventura, K., Jethalia, V., Coleman, C. J., Sridhar, S., Banerjee, A., Özakıncı, H., Mahendravarman, Y., Snioch, K., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101852 · Cited by 13

Stimulation of cGAS-STING pathway as a challenge in the treatment of small cell lung cancer: a feasible strategy?

Miglietta, G., Russo, M. V., Capranico, G., & Marinello, J. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02821-5 · Cited by 12

Small-cell lung cancer: anatomy of an immune-cold tumor

Millrine, D., Simpson, K., Blackhall, F. H., & Dive, C. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.11.011 · Cited by 3

Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection

Xu, H., Li, B., Yang, J., & Tang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1900927

Tumor cell plasticity and intrinsic immunogenicity: Implications for immunotherapy resistance in small‐cell lung cancer

Ruan, J. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14117 · Cited by 4

NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING

Kim, Y. S., Nabet, B. Y., Cortez, B. N., Sun, N.-Y., Sebastian, R., Redon, C. E., Ray, A., Liu, L., Ishola, A. A., Löw, S., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci185423 · Cited by 11

Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer

Seo, Y., Zhang, S., Jang, J., Ko, K.-P., Kim, K., Huang, Y., Kim, D. W., Kim, B.-J., Zou, G., Zhang, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67078-9 · Cited by 15